/
ARCT
$6.82-$0.06 (-0.87%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$195.6M
28M shares
52-week range
$5.85 – $24.17
5% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.52%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-27.02
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $15.8M | $20.8M | $9.5M | $12.4M | $205.8M | $157.7M | $138.4M | $67.2M |
| Cost of revenue | $17.0M | $0 | $55.9M | $0 | $0 | $0 | $0 | $3.0M |
| Gross profit | −$1.2M | $20.8M | −$46.4M | $12.4M | $205.8M | $157.7M | $138.4M | $64.2M |
| Gross margin | -7.8% | 100.0% | -486.5% | 100.0% | 100.0% | 100.0% | 100.0% | 95.5% |
| R&D | $17.0M | $33.6M | $57.8M | $173.8M | $147.8M | $192.1M | $195.2M | $112.2M |
| Operating income | −$21.8M | −$25.5M | −$71.5M | −$202.9M | $12.2M | −$78.2M | −$95.7M | −$75.0M |
| EBITDA | −$20.7M | −$24.5M | −$70.6M | −$199.8M | $15.2M | −$24.2M | −$77.4M | −$62.8M |
| Net income | −$21.8M | −$26.0M | −$72.1M | −$203.7M | $9.3M | −$29.7M | −$80.9M | −$65.8M |
| Net margin | -138.3% | -125.0% | -756.3% | -1648.0% | 4.5% | -18.8% | -58.5% | -97.9% |
| EPS (diluted) | -2.16 | -2.13 | -3.55 | -7.74 | 0.35 | -1.12 | -3.00 | -2.40 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $16M | $-4.06 | $-4.66–$-3.70 | 8 |
| 2027 | $35M | $-3.95 | $-4.85–$-3.07 | 8 |
| 2028 | $47M | $-3.49 | $-5.00–$-2.00 | 7 |
| 2029 | $134M | $-1.84 | $-6.26–$-0.36 | 2 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Arcturus Therapeutics Holdings Inc. Common Stock
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
www.arcturusrx.com- Employees
- 111
- IPO / List date
- May 22, 2013
- HQ
- SAN DIEGO, CA
Held by traders on TradeandTell
No one on the platform currently holds ARCT.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 178,300 | $1.4M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ARCT yet.
